.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
Johnson and Johnson
Citi
Covington
Deloitte
Accenture
Express Scripts
Cerilliant
Moodys

Generated: July 22, 2017

DrugPatentWatch Database Preview

EFFEXOR XR Drug Profile

« Back to Dashboard

What is the patent landscape for Effexor Xr, and what generic Effexor Xr alternatives are available?

Effexor Xr is a drug marketed by Wyeth Pharms Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-seven patent family members in forty-four countries.

The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are seventy drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

Summary for Tradename: EFFEXOR XR

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list17
Bulk Api Vendors: see list62
Clinical Trials: see list46
Patent Applications: see list1,575
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EFFEXOR XR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997ABRXYesNo6,274,171*PED► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997DISCNNoNo6,274,171*PED► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 1997ABRXYesNo6,274,171*PED► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 1997ABRXYesYes6,419,958*PED► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997DISCNNoNo6,403,120*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EFFEXOR XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 19976,310,101► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 19975,916,923*PED► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 19974,535,186*PED► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 19974,535,186*PED► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 19975,916,923*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EFFEXOR XR

Drugname Dosage Strength RLD Submissiondate
venlafaxine hydrochlorideExtended-release Tablets37.5 mg, 75 mg and 150 mgEffexor XR5/3/2007

International Patent Family for Tradename: EFFEXOR XR

Country Document Number Estimated Expiration
South Africa9810081► Subscribe
Australia747978► Subscribe
CroatiaP20000213► Subscribe
Poland188444► Subscribe
Spain2210454► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Express Scripts
Cantor Fitzgerald
Citi
McKesson
Daiichi Sankyo
Deloitte
Mallinckrodt
Cerilliant
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot